Payment overview · 2025
General Payments
$1,637.61
47 reported records · 9 companies
Healthcare provider profile · identity verified
Simon Li, MD
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · BROOKLYN, NY · NPI 1265751002
Verified facts
What the public records show
CMS Open Payments records show Simon Li, MD received $1,637.61 in general payments during 2025 across 47 reported records.
Gilead Sciences, Inc. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Prolia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Vemlidy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $385.83 | 23.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $384.54 | 23.5% | 12 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $293.72 | 17.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $278.22 | 17.0% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $120.84 | 7.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $115.39 | 7.0% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.22 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.97 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.88 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,637.61 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $293.72 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $292.36 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $278.22 | 14 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $205.37 | 10 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $120.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $70.39 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 192 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 301 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 99 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
192 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
57 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
301 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
215 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 2444 | 293 |
| Vascepa | Icosapent Ethyl | 2089 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 1907 | 235 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1681 | 208 |
| Simvastatin | Simvastatin | 1593 | 208 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1324 | 173 |
| Donepezil Hcl | Donepezil Hcl | 1054 | 140 |
| Tamsulosin Hcl | Tamsulosin Hcl | 967 | 124 |
| Omeprazole | Omeprazole | 829 | 201 |
| Metformin Hcl | Metformin Hcl | 782 | 108 |
| Meclizine Hcl | Meclizine Hcl | 687 | 210 |
| Metoprolol Succinate | Metoprolol Succinate | 669 | 88 |
| Ammonium Lactate | Ammonium Lactate | 621 | 144 |
| Alendronate Sodium | Alendronate Sodium | 576 | 75 |
| Montelukast Sodium | Montelukast Sodium | 573 | 87 |
| Clobetasol Propionate | Clobetasol Propionate | 571 | 161 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 526 | 107 |
| Finasteride | Finasteride | 466 | 57 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 430 | 117 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 424 | 93 |
| Naproxen | Naproxen | 413 | 160 |
| Raloxifene Hcl | Raloxifene Hcl | 411 | 49 |
| Azithromycin | Azithromycin | 378 | 266 |
| Glipizide | Glipizide | 375 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 369 | 45 |
| Trazodone Hcl | Trazodone Hcl | 344 | 118 |
| Allopurinol | Allopurinol | 328 | 50 |
| Januvia | Sitagliptin Phosphate | 328 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 302 | 90 |
| Farxiga | Dapagliflozin Propanediol | 301 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 36 |
| Celecoxib | Celecoxib | 293 | 85 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 289 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 288 | 96 |
| Bepotastine Besilate | Bepotastine Besilate | 286 | 76 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 275 | 47 |
| Atenolol | Atenolol | 270 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 38 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 247 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 231 | 27 |
| Sertraline Hcl | Sertraline Hcl | 228 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 224 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 215 | 44 |
| Vemlidy | Tenofovir Alafenamide | 215 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 43 |
| Jardiance | Empagliflozin | 214 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 26 |
| Promethazine Hcl | Promethazine Hcl | 201 | 154 |
| Glipizide Er | Glipizide | 200 | 29 |
| Azelastine Hcl | Azelastine Hcl | 199 | 53 |
| Procto-Med Hc | Hydrocortisone | 197 | 37 |
| Mometasone Furoate | Mometasone Furoate | 194 | 57 |
| Creon | Lipase/Protease/Amylase | 192 | 38 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 187 | 28 |
| Gabapentin | Gabapentin | 183 | 50 |
| Ketoconazole | Ketoconazole | 182 | 35 |
| Alcohol Pads | Alcohol Antiseptic Pads | 180 | 39 |
| Hydrocortisone | Hydrocortisone | 180 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 33 |
| Dexlansoprazole Dr | Dexlansoprazole | 168 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 167 | 40 |
| Ezetimibe | Ezetimibe | 167 | 22 |
| Halobetasol Propionate | Halobetasol Propionate | 165 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 19 |
| Lisinopril | Lisinopril | 162 | 17 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 144 | 29 |
| Glimepiride | Glimepiride | 140 | 14 |
| Restasis | Cyclosporine | 122 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 40 |
| Amoxicillin | Amoxicillin | 117 | 77 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 113 | 92 |
| Famotidine | Famotidine | 106 | 29 |
| Eliquis | Apixaban | 105 | 20 |
| Linzess | Linaclotide | 99 | 23 |
| Loperamide | Loperamide Hcl | 99 | 74 |
| Nateglinide | Nateglinide | 99 | 12 |
| Xarelto | Rivaroxaban | 99 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 97 | 19 |
| Tradjenta | Linagliptin | 97 | 12 |
| Carvedilol | Carvedilol | 96 | 13 |
| Fenofibrate | Fenofibrate | 94 | 11 |
| Lidocaine | Lidocaine | 93 | 37 |
| Metformin Hcl Er | Metformin Hcl | 85 | suppressed |
| Gemfibrozil | Gemfibrozil | 79 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 79 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 74 | 43 |
| Memantine Hcl Er | Memantine Hcl | 73 | suppressed |
| Telmisartan | Telmisartan | 73 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | 40 |
| Methimazole | Methimazole | 69 | suppressed |
| Dutasteride | Dutasteride | 67 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 66 | suppressed |
| Nexium | Esomeprazole Magnesium | 66 | 11 |
| Memantine Hcl | Memantine Hcl | 65 | suppressed |
| Proctozone-Hc | Hydrocortisone | 65 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | suppressed |
| Mupirocin | Mupirocin | 64 | 37 |
| Colchicine | Colchicine | 59 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | suppressed |
| Meloxicam | Meloxicam | 58 | 16 |
| Prolia | Denosumab | 57 | 34 |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 52 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Olanzapine | Olanzapine | 50 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 50 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 47 | 14 |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 44 | suppressed |
| Nexletol | Bempedoic Acid | 44 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 43 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 43 | 14 |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Tacrolimus | Tacrolimus | 42 | suppressed |
| Repaglinide | Repaglinide | 41 | suppressed |
| Acarbose | Acarbose | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 28 |
| Kerendia | Finerenone | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 39 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 39 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | suppressed |
| Fluocinonide | Fluocinonide | 37 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 12 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Calcitriol | Calcitriol | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Brilinta | Ticagrelor | 32 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 26 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Silodosin | Silodosin | 31 | suppressed |
| Ursodiol | Ursodiol | 30 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Ciclopirox | Ciclopirox | 28 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 28 | 20 |
| Valacyclovir | Valacyclovir Hcl | 28 | 20 |
| Metformin Er Gastric | Metformin Hcl | 27 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | 21 |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Ofloxacin | Ofloxacin | 24 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 23 | suppressed |
| Tavaborole | Tavaborole | 23 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 20 |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 21 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | 14 |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Micardis | Telmisartan | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,637.61 · 47 records | Gilead Sciences, Inc. | CREON, Cologuard Collection Kit, EVENITY, FARXIGA, LINZESS, Leqembi, Livdelzi, OTEZLA, PROLIA, REPATHA, REZDIFFRA, XIFAXAN, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error